MXPA05006033A - Determinantes moleculares de enfermedad osea por mieloma, y usos de los mismos. - Google Patents

Determinantes moleculares de enfermedad osea por mieloma, y usos de los mismos.

Info

Publication number
MXPA05006033A
MXPA05006033A MXPA05006033A MXPA05006033A MXPA05006033A MX PA05006033 A MXPA05006033 A MX PA05006033A MX PA05006033 A MXPA05006033 A MX PA05006033A MX PA05006033 A MXPA05006033 A MX PA05006033A MX PA05006033 A MXPA05006033 A MX PA05006033A
Authority
MX
Mexico
Prior art keywords
bone disease
lytic
lesions
bone
multiple myeloma
Prior art date
Application number
MXPA05006033A
Other languages
English (en)
Inventor
John D Shaughnessy
Original Assignee
Univ Arkansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arkansas filed Critical Univ Arkansas
Publication of MXPA05006033A publication Critical patent/MXPA05006033A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

Para identificar determinantes moleculares de enfermedad osea litica en mieloma multiple, se compararon los perfiles de expresion de aproximadamente 12,000 genes en celulas plasmaticas enriquecidas con CD 138 de pacientes con mieloma multiple recien diagnosticado que no exhiben evidencia radiologica de lesiones liticas (n = 28), con aquellos con = 3 lesiones liticas (n = 47); dos antagonistas de la senalizacion de WNT secretados, proteina 3 relacionada al receptor rizado soluble (SFRP-3/FRZB) y el homologo de Dickkopf-1 (DKK1) de humano, fueron expresados en 40 de 47 con lesiones oseas liticas, pero solo 16 de 28 que carecian de lesiones oseas (P < .O5) DKK1 y FRZB no fueron expresados en celulas plasmaticas de 45 donadores de medula osea normal o 10 con macroglobulinemia de Waldenstrom, una malignidad de celulas plasmaticas relacionada que carece de enfermedad osea; estos datos indican que estos factores son mediadores importantes de enfermedad osea por mieloma multiple, y que pueden usarse inhibidores de estas proteinas para bloquear la enfermedad osea.
MXPA05006033A 2002-12-05 2003-12-04 Determinantes moleculares de enfermedad osea por mieloma, y usos de los mismos. MXPA05006033A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43104002P 2002-12-05 2002-12-05
PCT/US2003/038372 WO2004053063A2 (en) 2002-12-05 2003-12-04 Molecular determinants of myeloma bone disease and uses thereof

Publications (1)

Publication Number Publication Date
MXPA05006033A true MXPA05006033A (es) 2006-03-08

Family

ID=32507666

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05006033A MXPA05006033A (es) 2002-12-05 2003-12-04 Determinantes moleculares de enfermedad osea por mieloma, y usos de los mismos.

Country Status (11)

Country Link
US (1) US7459437B2 (es)
EP (2) EP1913952B1 (es)
JP (2) JP4874549B2 (es)
AT (1) ATE500837T1 (es)
AU (1) AU2003302926A1 (es)
CA (1) CA2507496C (es)
DE (1) DE60336356D1 (es)
ES (1) ES2362681T3 (es)
MX (1) MXPA05006033A (es)
PT (1) PT1913952E (es)
WO (1) WO2004053063A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7811750B2 (en) * 2002-12-05 2010-10-12 Board Of Trustees Of The University Of Arkansas Molecular determinants of myeloma bone disease and use thereof
WO2005070448A2 (en) * 2004-01-21 2005-08-04 Five Prime Therapeutics, Inc. Methods of use for secreted frizzled-related protein 3 (sfrp-3) in the prevention and treatment of disease
ES2414460T3 (es) * 2004-08-04 2013-07-19 Amgen Inc. Anticuerpos para Dkk-1
WO2006061430A2 (en) * 2004-12-10 2006-06-15 Proskelia Bone metastasis markers as a target regulating bone metastasis and bone development
JP2006217844A (ja) * 2005-02-09 2006-08-24 Univ Of Tokyo Ｄｋｋ１の遺伝子、蛋白質及び抗体を用いた癌の診断・モニター方法及び治療方法
AR060017A1 (es) 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
WO2007104181A1 (fr) 2006-03-13 2007-09-20 Shanghai Cancer Institute Utilisations de la protéine dkk-1 dans le diagnostic de cancers
WO2009132815A1 (en) 2008-04-30 2009-11-05 Roche Diagnostics Gmbh Use of sfrp-3 in the assessment of heart failure
NZ596274A (en) 2009-05-12 2013-11-29 Pfizer Blocking anti-dkk-1 antibodies and their uses
BR112012029656A2 (pt) * 2010-05-21 2016-12-13 Uni Fur Bodenkultur Wien composições para uso no tratamento ou diagnóstico de disturbios ósseos e/ou distúrbios cardiovasculares
ES2624981T3 (es) 2011-07-01 2017-07-18 Dana-Farber Cancer Institute, Inc. Descubrimiento de una mutación somática en el gen MYD88 en linfoma linfoplasmocitario
EP2744916A4 (en) 2011-07-13 2015-06-17 Primeradx Inc MULTIMODAL METHODS FOR SIMULTANEOUS DETECTION AND QUANTIFICATION OF MULTIPLE NUCLEIC ACIDS IN A SAMPLE
AU2014318614B2 (en) 2013-09-12 2021-01-07 Dana-Farber Cancer Institute Inc. Methods for evaluating and treating Waldenstrom's macroglobulinemia
AU2014360426B2 (en) 2013-12-06 2020-05-07 Dana-Farber Cancer Institute, Inc. Methods to distinguish Waldenstrom's Macroglobulinemia from IgM monoclonal gammopathy of undetermined significance
JP2019518006A (ja) 2016-04-29 2019-06-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｙｄ８８変異型疾患における治療標的としてのｈｃｋ

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3510200A (en) * 1999-03-05 2000-09-21 Millennium Pharmaceuticals, Inc. Human dickkopf-related protein and nucleic acid molecules and uses therefor
IL148421A0 (en) * 1999-09-13 2002-09-12 American Home Prod Pharmaceutical compositions and methods of using secreted frizzled related protein
BR0209836A (pt) * 2001-05-17 2004-12-07 Genome Therapeutics Corp Método para regular a atividade de lrp5, lrp6 ou hbm em um paciente, e do caminho dkk-wnt em um paciente, para modular a massa óssea e os nìveis de lipìdeo em um paciente, para diagnosticar a massa óssea alta ou baixa e/ou os nìveis de lipìdeos altos ou baixos em um paciente, para triar um composto que modula a interação de dkk com lrp5, lrp6, hbm ou um fragmento de ligação de dkk de lrp5, lrp6 ou hbm, e de dkk com uma proteìna que interage com a dkk, composição, composição farmacêutica, métodos para identificar compostos que modulem as interações da dkk e lrp5/lrp6/hbm, e para identificar parceiros de ligação para uma proteìna de dkk, ácido nucléico que codifica um aptâmero peptìdico da proteìna que interage com dkk, vetor, método para detectar uma atividade moduladora de um composto, animal transgênico, método para identificar compostos potenciais que modulem a atividade da dkk, aptâmero peptìdico, anticorpo ou fragmento de anticorpo, e, métodos para identificar proteìnas que interagem com a dkk modulando a interação da dkk com o caminho de sinalização wnt, para identificar compostos que modulem a interação da dkk com o caminho de sinalização wnt, para testar compostos que modulam a atividade mediada pela dkk em um mamìfero, e para triar compostos ou composições que modulam a interação da dkk e uma proteìna que interage com a dkk
US20040038860A1 (en) 2002-05-17 2004-02-26 Allen Kristina M. Reagents and methods for modulating dkk-mediated interactions

Also Published As

Publication number Publication date
EP1567663A2 (en) 2005-08-31
WO2004053063A2 (en) 2004-06-24
ES2362681T3 (es) 2011-07-11
DE60336356D1 (de) 2011-04-21
JP5432966B2 (ja) 2014-03-05
PT1913952E (pt) 2011-04-14
JP4874549B2 (ja) 2012-02-15
CA2507496A1 (en) 2004-06-24
ATE500837T1 (de) 2011-03-15
EP1567663A4 (en) 2006-04-19
US7459437B2 (en) 2008-12-02
AU2003302926A1 (en) 2004-06-30
CA2507496C (en) 2014-11-04
WO2004053063A3 (en) 2004-11-25
JP2006512911A (ja) 2006-04-20
US20040137489A1 (en) 2004-07-15
AU2003302926A8 (en) 2004-06-30
EP1913952B1 (en) 2011-03-09
JP2012046535A (ja) 2012-03-08
EP1913952A1 (en) 2008-04-23

Similar Documents

Publication Publication Date Title
MXPA05006033A (es) Determinantes moleculares de enfermedad osea por mieloma, y usos de los mismos.
Chu et al. Mosaic structure of globular domains in the human type VI collagen alpha 3 chain: similarity to von Willebrand factor, fibronectin, actin, salivary proteins and aprotinin type protease inhibitors.
Pope et al. COL3A1 mutations cause variable clinical phenotypes including acrogeria and vascular rupture
Seldin et al. Argentine population genetic structure: large variance in Amerindian contribution
WO2003042661A8 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
DE60335069D1 (de) Verfahren zur Herstellung von kryogen zerkleinerten Legierungen für strangegepressten und geschmiedeten Bauteile
WO2010132725A3 (en) Cyclin dependent kinase inhibitors and methods of use
WO2005033333A3 (en) Methods and compositions for the diagnosis of cancer
Singh et al. Identification of matrix metalloproteinases and their tissue inhibitors type 1 and 2 in human masseter muscle
Frisk et al. Goltz syndrome in males: A clinical report of a male patient carrying a novel PORCN variant and a review of the literature
Baboolal et al. Intrinsic multipotential mesenchymal stromal cell activity in gelatinous Heberden’s nodes in osteoarthritis at clinical presentation
Calvo et al. Type XIX collagen: a promising biomarker from the basement membranes
WO1999054353A3 (de) Menschliche nukleinsäuresequenzen aus uterusnormalgewebe
NO20060781L (no) Anvendelse av loselig CD164 ved inflammatoriske og/eller autoimmune lidelser
ATE366936T1 (de) Zusammensetzungen und verfahren zur verwendung von fibronektin-fragmenten bei krebsdiagnose
DE60312684D1 (de) Plazenta-wachstumsfaktor als target für die behandlung von osteoporose
Chen et al. 6p21. 2–p12. 3 deletion detected by aCGH in an 8-year-old girl with cleidocranial dysplasia and developmental delay
IL169256A0 (en) Metalloprotease proteins
Silva-Filho et al. How laminin-1 can be recognized by the protozoan parasite Tritrichomonas foetus: possible role played by the extracellular matrix glycoprotein in both cytoadhesion and cytotoxicity exerted by the parasite
WO1999054448A3 (de) Menschliche nukleinsäurefragmente, deren expression in uterusmyomgewebeerhoeht ist
Mohammadi-Asl et al. A novel pathogenic variant in the FZD6 gene causes recessive nail dysplasia in a large Iranian kindred
NO20052525D0 (no) Spleisevariant av humant hypofyseveksthormon
Quarnstrom et al. Repairing fractured porcelain-fused-to-metal bridge pontics
Ivaškevičius et al. Identification of Novel and Recurrent Mutations in F13B Gene Leading to FXIII Deficiency
Copeland A COMPREHENSIVE FORENSIC CASE REPORT FOR THE BONNER COUNTY CORONER CASE# 20-100

Legal Events

Date Code Title Description
FG Grant or registration